M&A Deal Summary

Supernus Pharmaceuticals Acquires Biscayne Neurotherapeutics

On September 13, 2018, Supernus Pharmaceuticals acquired life science company Biscayne Neurotherapeutics for 15M USD

Acquisition Highlights
  • This is Supernus Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Supernus Pharmaceuticals’ 2nd largest (disclosed) transaction.
  • This is Supernus Pharmaceuticals’ 1st transaction in the United States.
  • This is Supernus Pharmaceuticals’ 1st transaction in Florida.

M&A Deal Summary
Date 2018-09-13
Target Biscayne Neurotherapeutics
Sector Life Science
Buyer(s) Supernus Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 15M USD

Target

Biscayne Neurotherapeutics

Miami, Florida, United States
Biscayne Neurotherapeutics is a developer of a novel treatment for epilepsy. Biscayne Neurotherapeutics is based in Miami, Florida.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Supernus Pharmaceuticals

Rockville, Maryland, United States
Category Company
Founded 2005
Sector Life Science
Employees652
Revenue 608M USD (2023)
DESCRIPTION

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Supernus Pharmaceuticals was founded in 2005 and is based in Rockville, Maryland.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 2
State (Florida) 1 of 1
Country (United States) 1 of 3
Year (2018) 1 of 1
Size (of disclosed) 2 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-09 US WorldMeds - CNS Portfolio

Kentucky, United States

US WorldMeds LLC - CNS Portfolio (central nervous system) is involved in developing and commercializing products for the treatment of Parkinson’s disease.

Buy -
Mergr

Product

Company

Legal